Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-08046033 in Advanced Solid Tumors
NCT07519655Phase 1Recruiting
- Sponsor
- Pfizer
- Start
- Apr 2026
- Primary completion
- Jul 2028
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 1, open-label trial of PF-08046033 in non-small cell lung cancer (NSCLC), Esophageal Squamous Cell Carcinoma (ESCC) and melanoma (10 cohorts), sponsored by Pfizer. Primary endpoints: Adverse Events at 1 year, Laboratory abnormalities at 1 year and 3 more. Started Apr 2026; status: recruiting.
02
Drugs
PF-08046033
03
Conditions
non-small cell lung cancer (NSCLC)Esophageal Squamous Cell Carcinoma (ESCC)melanoma
Beyond the preview
Go deeper on NCT07519655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07519655.